A Study of EBC-129 in Advanced Solid Tumours
This study is testing a new drug called EBC-129, both on its own and in combination with pembrolizumab, for people with advanced solid tumors. These are cancers that have spread or cannot be removed by surgery, and for which standard treatments are no longer working or are not tolerated. The main goals are to understand the safety of EBC-129 and to find the best dose to use in future studies. The study plans to enroll 98 participants. You might be able to join if you are an adult (18 or older) with a solid tumor that has progressed and meets specific weight requirements. The study is currently recruiting, but the exact status is unclear.
- Study design
- This is an open-label study, meaning you and your doctors will know which treatment you are receiving. It is divided into four parts and plans to enroll 98 participants.
- What's involved
- You will receive EBC-129 through an IV (intravenous) infusion on Day 1 of each 21-day cycle, or multiple doses starting from Day 1 for 21-day or 28-day cycles. If you are in a combination part of the study, you will also receive pembrolizumab every 21 days.
- Compensation
- Not stated in the trial record.
- Follow-up
- You will be followed from before treatment starts until 30 days after your last dose, which is expected to be for approximately 2 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study of EBC-129 in Advanced Solid Tumours
At a glance
Conditions
NCT05701527
Where you'd take part
This study runs at 5 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
National Cancer Centre Singapore
Singapore, South West, Singaporeno site contact published
Recruiting
National University Hospital - Medical Oncology
Singapore, South West, Singaporeno site contact published
Recruiting
Taipei Veterans General Hospital
Taipei, Taipei, Taiwanno site contact published
Not yet recruiting
University of Colorado Hospital (UCH) - University of Colorado Cancer Center (UCCC) - Neuroendocrine Tumor Center
Aurora, Coloradono site contact published
Recruiting
UT MD Anderson Cancer Center
Houston, Texasno site contact published
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Venkateshan Srirangam Prativadibhayankara, MD · STUDY_DIRECTOR · EDDC (Experimental Drug Development Centre), A*STAR Research Entities
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Part A, Part B, Part C and Part D- Number of patients with serious adverse events (SAEs) and treatment emergent adverse events (TEAEs)From pre-screening (≥28 days from planned date of treatment i.e. Day 1) until end of study (EOS i.e., 30 days from last dose). Approximately 2 years
- Part A, Part B and Part D- Determination of Maximum tolerated dose (MTD)Approximately 2 years
- Part A, Part B and Part D- Determination of the Recommended Phase 2 dose (RP2D)Approximately 2 years
- Part C- Objective response rate (ORR)Day 1 through 12 cycles (each cycle is 21 days)
The number (%) of patients with a best overall response of complete response (CR) or partial response (PR) per RECIST v1.1 as assessed by investigator.
- Part D- ORRDay 1 through 12 cycles (each cycle is 21 or 28 days)
The number (%) of patients with a best overall response of CR or PR per RECIST v1.1 as assessed by investigator.